The FDA has approved subcutaneous daratumumab and hyaluronidase-fihj (Darzalex Faspro) for use in patients with high-risk ...
An advanced practice provider (APP)-led peer review quality assurance (QA) committee was found to be feasible and identified ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback